

MAY 18 2005

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number

10/632,706

Filing Date

August 1, 2003

First Named Inventor

James D. Marks

Group Art Unit

1645

Examiner Name

Virginia Allen Portner

Attorney Docket Number

407T-895120US

ENCLOSURES (check all that apply)

 Fee Transmittal Form Fee Attached Amendment / Response After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 Assignment Papers
(for an Application) Drawing(s) Licensing-related Papers Petition Routing Slip (PTO/SB/69) and Accompanying Pétition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Small Entity Statement Request for Refund After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group
(Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Additional Enclosure(s)
*(please identify below):*64 Enclosed References
receipt acknowledgment postcard

Authorization to Charge Deposit Account

Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm
or
Individual name

Tom Hunter, Reg. No. 38,498,

Quine Intellectual Property Law Group P.C.

Signature

Date

May 16, 2005

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, DC 20231 on this date: May 16, 2005

Typed or printed name

Chianti Appling

Signature

Date

5/16/05

O I P E S C I
MAY 18 2005

U.S. TRADEMARK OFFICE

I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on May 16, 2005

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By

Chianti Appino

Attorney Docket No. 407T-895120US
Client Ref. No. 1998-013-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

James D. Marks, et al.

Application No.: 10/632,706

Filed: August 1, 2003

For: THERAPEUTIC MONOCLONAL
ANTIBODIES THAT NEUTRALIZE
BOTULINUM NEUROTOXINS

Confirmation No. 5306

Examiner: Virginia Allen Portner

Art Unit: 1645

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR § 1.97 and
§ 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action on the merits per 37 CFR 1.97(b)(3). However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.


Respectfully submitted,



Tom Hunter, J.D., Ph.D.
Reg. No. 38,498

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P.O. BOX 458
Alameda, CA 94501
(510) 337-7871
Fax (510) 337-7877

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

 <p>Substitute for form 1449A-B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>MAY 18 2005</p> <p>(use as many sheets as necessary)</p>		Complete if Known	
		Application Number	10/632,706
		Filing Date	August 1, 2003
		First Named Inventor	James D. Marks
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	407T-895120US
Date Submitted	May 16, 2005		

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
	1.	4,689,299		Insel et al.	08/25/1987	
	2.	5,306,730		Nagai et al.	04/26/1994	
	3.	5,807,741		Brown et al.	9/15/1998	
	4.	5,919,665		Williams	07/06/1999	
	5.	5,932,449		Emanuel et al.	8/3/1999	
	6.	6,331,402		Nussbaum et al.	12/18/2001	
	7.	6,416,947		Balasubramanian et al.	07/09/2002	
	8.	6,495,143		Lee et a.	12/17/2002	
	9.	6,667,158		Bavari et al.	12/23/2003	
	10.	6,841,156		Aoki et al.	01/11/2005	
	11.	2002/0155114		Marks	10/24/2002	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	12.	WO	00/69891		Dept of the Army	11/23/2000		
	13.	WO	00/69895		Dept of the Army	11/23/2000		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	14.	Amersdorfer <i>et al.</i> (1997) <i>Infect. Immun.</i> , 65: 3743-3752	
	15.	Amersdorfer <i>et al.</i> (2002) <i>Vaccine</i> 20: 1640-1648	
	16.	Arnon (1993) Pp. 477-482 in <i>Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects</i> , ed. DasGupta, B. R. Plenum, New York	
	17.	Arnon <i>et al.</i> (2001) <i>J. Am. Med. Assoc.</i> 285: 1059-1070	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/632,706
		Filing Date	August 1, 2003
		First Named Inventor	James D. Marks
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	407T-895120US
Date Submitted	May 16, 2005		

	18.	Atassi (1996) <i>J. Protein Chem.</i> , 15: 691-699	
	19.	Atassi (1996) <i>J. Protein Chem.</i> , 15: 691-699	
	20.	Black and Gunn. (1980) <i>Am. J. Med.</i> , 69: 567-570	
	21.	Black, <i>et al.</i> (1980) <i>Am. J. Med.</i> , 69:567-570	
	22.	Black, <i>et al.</i> (1986) <i>J. Cell Biol.</i> , 103:521-534	
	23.	Bowmer (1963) <i>Bull. W. H. O.</i> 29: 701-709	
	24.	Byrne and Smith (2000) <i>Biochimie</i> 82: 955-966	
	25.	Chen et al. (1997) <i>Infect. Immun.</i> 65(5): 1626-1630	
	26.	Chen et al. (1998) <i>Infect. Immun.</i> , 66: 2420-2425	
	27.	Colcher <i>et al.</i> (1990) <i>J. Natl. Cancer Inst.</i> 82: 1191-1197	
	28.	Daniels-Holgate <i>et al.</i> (1996) <i>J. Neurosci. Res.</i> 44:263-271	
	29.	Demarchi, <i>et al.</i> (1958) <i>Bull. Acad. Nat. Med.</i> , 142: 580-582	
	30.	Dolly <i>et al.</i> (1984) <i>Nature (London)</i> 307: 457-460	
	31.	Emanuel <i>et al.</i> (1996) <i>J. Immunol. Meth.</i> , 193: 189-197	
	32.	Fitzsimmons <i>et al.</i> (2000) <i>Vaccine</i> 19: 114-121	
	33.	Foote and Milstein (1991) <i>Nature</i> , 352:530-532	
	34.	Foote, <i>et al.</i> (1991) <i>Nature</i> 352: 530-532	
	35.	Fotinou <i>et al.</i> (2001) <i>J. Biol. Chem.</i> 276: 32274-32281	
	36.	Franz et al. (1993) Pp. 473-476 in Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects, ed. DasGupta, B. R. Plenum, New York	
	37.	Gibson <i>et al.</i> (1988) <i>J. Appl. Bacteriol.</i> , 64: 285-291	
	38.	Gill (1982) <i>Microbiol. Rev.</i> 46: 86-94	
	39.	Hallis et al. (1993) Pp. 433-436 In: Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects, ed. DasGupta, B. R., Plenum, New York	
	40.	Hathaway, <i>et al.</i> (1984) <i>J. Infect. Dis.</i> 150:407-412	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/632,706
		Filing Date	August 1, 2003
		First Named Inventor	James D. Marks
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	407T-895120US
Date Submitted	May 16, 2005		

	41.	Hatheway (1995) <i>Curr. Top. Microbio. Immunol.</i> , 195: 55-75	
	42.	Hatheway and Dang (1994) Pp. 93-107 In: <i>Therapy with Botulinum Toxin</i> , ed. Jankovic, J., Dekker, New York	
	43.	Hatheway <i>et al.</i> (1984) <i>J. Infect. Dis.</i> , 150: 407-412	
	44.	Hibbs <i>et al.</i> (1996) <i>Clin. Infect. Dis.</i> , 23: 337-340	
	45.	Hildebrand, et al. (1961) <i>Proc. Soc. Exp. Biol. Med.</i> 107:284-289	
	46.	Huston, et al.,(1996) <i>J. Nucl. Med.</i> 40: 320	
	47.	Koriazova and Montal (2003) <i>Nat. Struct. Biol.</i> , 10: 13-18	
	48.	Kozaki <i>et al.</i> (1986) <i>Infect. Immun.</i> , 52: 786-791	
	49.	Kozaki et al. (1995) <i>Microbiol. Immunol.</i> , 39: 767-774	
	50.	Kozaki <i>et al.</i> (1998) <i>Infect. Immun.</i> , 66: 4811-4816	
	51.	Lacy and Stevens (1999) <i>J. Mol. Biol.</i> 291: 1091-1104	
	52.	Lacy et al. (1998) <i>Nat. Struct. Biol.</i> 5: 898-902	
	53.	Lang, et al. (1993) <i>J. Immunol.</i> 151: 466-473	
	54.	Mahant et al. (2000) <i>J. Clin. Neurosci.</i> 7: 389-394	
	55.	Middlebrook and Franz (1997) Botulinum Toxins, chapter 33. In F.R. Sidell, E.T. Takafuji, D.R. Franz (eds.), <i>Medical Aspects of Chemical and Biological Warfare</i> . TMM publications, Washington, D.C.	
	56.	Middlebrook, et al. (1995) <i>Curr. Top. Microbiol. Immunol.</i> 195:89-122	
	57.	Montecucco (1986) <i>Trends Biochem. Sci.</i> 11:314-317	
	58.	Montecucco and Schiavo (1995) <i>Q. Rev. Biophys.</i> 28: 423-472	
	59.	Montero-Julian <i>et al.</i> (1995) <i>Blood</i> 85: 917-924	
	60.	Mullaney <i>et al.</i> (2001) <i>Infect. Immun.</i> 69: 6511-6514	
	61.	Nowakowski <i>et al.</i> (2002) <i>Proc. Natl. Acad. Sci. U S A</i> , 99: 11346-11350	
	62.	Oguma <i>et al.</i> (1990) <i>Lancet</i> 336: 1449-1450	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/632,706
		Filing Date	August 1, 2003
		First Named Inventor	James D. Marks
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	407T-895120US
Date Submitted	May 16, 2005		

	63.	Pless et al. (2001) <i>Infect. Immun.</i> 69: 570–574	
	64.	Reichert (2001) <i>Nat. Biotechnol.</i> 19: 819–822	
	65.	Schengrund (1999) <i>J Toxicol Toxin Rev.</i> , 18: 35–44	
	66.	Schiavo et al. (1992) <i>Nature</i> (London) 359: 832–835	
	67.	Schiavo et al. (1993) <i>J. Biol. Chem.</i> 268: 23784–23787	
	68.	Schier et al. (1995) <i>Immunotechnology</i> , 1: 73-81	
	69.	Siegel (1988) <i>J. Clin. Microbiol.</i> 26: 2351-2356	
	70.	Simpson (1980) <i>J. Pharmacol. Exp. Ther.</i> 212: 16–21	
	71.	Sonnabend et al. (1981) <i>J. Infect. Dis.</i> , 143: 22-27	
	72.	Tacket et al. <i>Am. J. Med.</i> , 76: 794-798	
	73.	Volk et al. (1984) <i>Infect. Immun.</i> 45: 604–609	
	74.	Williams et al. (1983) <i>Eur. J. Biochem.</i> , 131: 437-445	
	75.	Zwick et al. (2001) <i>J. Virol.</i> 75: 12198–12208	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.